Gloucester Pharmaceuticals Announces Presentation of Romidepsin Data for T-cell Lymphomas at the 2006 American Society of Hematology (ASH) Annual Meeting.- data from over 100 patients in ongoing cutaneous T-cell lymphoma Cutaneous T-Cell Lymphoma Definition Cutaneous T-cell lymphoma (CTCL) is a malignancy of the T-helper (CD4+) cells of the immune system. Description (CTCL CTCL Cutaneous T Cell Lymphoma ) and peripheral T-cell lymphoma (PTCL) studies to be presented - CAMBRIDGE, Mass. -- Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that two abstracts detailing updated results from clinical trials of the Company's lead product candidate, romidepsin (formerly known as depsipeptide, FK228), for the treatment of T-cell lymphomas will be presented at the 2006 American Society of Hematology's 48th Annual Meeting, to be held December 9-12 in Orlando, FL. Dr. Adam Lerner of the Boston University School of Medicine Boston University School of Medicine (BUSM) is one of the graduate schools of Boston University. It is an American medical school located in the South End neighborhood of Boston, Massachusetts. will present Abstract #2468 "Romidepsin (Depsipeptide, FK228) Induces Clinically Significant Responses in Treatment-Refractory CTCL: Interim Report of a Phase II Multicenter Study" in a general poster session on Sunday, December 10, 2006. The poster will report on interim data from 43 patients in Gloucester's ongoing pivotal trial for CTCL. Dr. Richard L. Piekarz of the National Cancer Institute (NCI See Liberate. ) will present Abstract #2469 "Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Medical Markers" in a general poster session on Sunday, December 10, 2006. Dr. Piekarz, a principal investigator in the NCI's ongoing clinical trial of romidepsin, will report on interim results from this phase II study. Copies of these abstracts and others relating to romidepsin are now available and can be viewed on-line through the ASH website: www.hematology.org. Access to the on-line abstracts requires a free registration. Gloucester also announced that it will be sponsoring a medical information exhibit in Booth #1137 during the meeting. Members of Gloucester's clinical affairs staff will be available to discuss the Company's clinical development plans and corporate activities. About Romidepsin (Depsipeptide) In July 2006 the International Nonproprietary Names (INN) body of the World Health Organization (WHO) and the United States Adopted Names United States Adopted Names See USAN. (USAN USAN United States Adopted Name. USAN abbr. United States Adopted Names (used for nonproprietary names of drugs adopted by a committee of medical professionals and drug manufacturers) USAN ) Council approved the nonproprietary (generic) name romidepsin for depsipeptide (FK228). Romidepsin is a novel agent in a new class of anti-cancer drugs known as histone deacetylase inhibitors. The Company is currently conducting a pivotal study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL). Romidepsin has received both Fast Track and Orphan Drug Designation by the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ), and Orphan Drug Designation from the European Agency for the Evaluation of Medicinal Products (EMEA). Romidepsin is also in clinical trials for a variety of other hematologic malignancies and solid tumors including peripheral T-cell lymphoma, hormone refractory prostate cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer institute (NCI), under a Cooperative Research and Development Agreement “CRADA” redirects here. For other uses, see CRADA (disambiguation). A Cooperative Research and Development Agreement (CRADA) is an agreement between a government agency and a private company to work together. (CRADA CRADA Cooperative Research And Development Agreement ) with the Company. About Gloucester Pharmaceuticals, Inc. Gloucester Pharmaceuticals, Inc. is a privately held, venture-backed company that develops and commercializes innovative products for the treatment of cancer patients. Gloucester is headquartered in Cambridge, MA. For more information on Gloucester and our clinical development program visit our website at www.gloucesterpharma.com or call 888-GPI-CTCL (888-474-2825). |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion